Atopic dermatitis patients refractory to topical therapy have few treatment options. This study evaluated the efficacy of the newly approved biologic dupilumab in this difficult-to-treat population.
The British Journal of Dermatology
Original Article: Dupilumab With Topical Corticosteroids for Atopic Dermatitis